Skip to main content

Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine

Heavy hearts soared Monday with news that Moderna's Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.